Virtual pharmaceutical companies: Collaborating flexibly in pharmaceutical development

Drug Discovery Today

Volumn 19, Issue 3, 2014, Pages 348-355

  Forster, Simon P ^a   Stegmaier, Julia ^b   Spycher, Rene ^c   Seeger, Stefan ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b LifeScan Division of Cilag GmbH International Johnson and Johnson   (Switzerland)

^c Janssen Pharmaceuticals Pharmaceutical Development and Manufacturing Sciences Johnson and Johnson   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG RESEARCH; HUMAN; REVIEW; VIRTUAL PHARMACEUTICAL COMPANY; COMPUTER INTERFACE; COOPERATION; DRUG DESIGN; ECONOMICS; NONBIOLOGICAL MODEL; ORGANIZATION AND MANAGEMENT; RESEARCH;

COOPERATIVE BEHAVIOR; DRUG DESIGN; DRUG INDUSTRY; HUMANS; MODELS, ORGANIZATIONAL; RESEARCH; USER-COMPUTER INTERFACE;

EID: 84896390095     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2013.11.015     Document Type: Review

References (26)

1. I. Khanna Drug discovery in pharmaceutical industry: productivity challenges and trends Drug Discov. Today 17 2012 1088 1102
2. Y.L. Bennani Drug discovery in the next decade: innovation needed ASAP Drug Discov. Today 16 2011 779 792
3. C. Harrison The patent cliff steepens Nat. Rev. Drug Discov. 10 2011 12 13
4. M. Goodman Pharmaceutical industry financial performance Nat. Rev. Drug Discov. 8 2009 927 928
5. B. Munos Lessons from 60 years of pharmaceutical innovation Nat. Rev. Drug Discov. 8 2009 959 968
6. F. Ullman, and R. Boutellier A case study of lean drug discovery: from project driven research to innovation studios and process factories Nat. Rev. Drug Discov. 13 2008 543 550
7. J.-P. Garnier Rebuilding the R&D Engine in Big Pharma Harvard Bus. Rev. 86 2008 68 76
8. S.M. Paul et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge Nat. Rev. Drug Discov. 9 2010 203 214
9. M.J. Belsey Drug developer strategies to boost competitiveness Nat. Rev. Drug Discov. 6 2007 265 266 (Pubitemid 46505876)
10. S. Ekins et al. Four disruptive strategies for removing drug discovery bottlenecks Drug Discov. Today 18 2013 265 271
11. R. Wellenreuther et al. Promoting drug discovery by collaborative innovation: a novel risk- and reward-sharing partnership between the German Cancer Research Center and Bayer HealthCare Drug Discov. Today 17 2012 1242 1248
12. S. Hutchins et al. Open partnering of integrated drug discovery: continuing evolution of the pharmaceutical model Drug Discov. Today 16 2011 281 283
13. M. Lessl et al. Grants4Targets - an innovative approach to translate ideas from basic research into novel drugs Drug Discov. Today 16 2011 288 292
14. G.A.M. Giardina, and L.F. Raveglia Creating effective medicinal chemistry collaborations in drug discovery Future Med. Chem. 1 2009 3 6
15. T. Kelly, and C. Nickum Knowledge-based outsourcing: driving deeper insights Pharm. Executive 30 2010 39 44
16. R.N. Lawrence Alastair Devlin discusses the concept of virtual pharma companies Drug Discov. Today 6 2001 508 509
17. R. Longman Lilly's chorus experiment In Vivo Bus. Med. Rep. 25 2007 35 39
18. R. Longman Flexion: the in-licensing advantage of cheap proof-of-concept Start-up 12 2007 1 2
19. E. Bonabeau et al. A more rational approach to new-product development Harvard Bus. Rev. 86 2008 96 102
20. D. Nicol et al. A role for virtual biotechnology companies in drug discovery and development? J. Commercial Biotechnol. 19 2013 10 19
21. B. Love Virtual pharmaceutical R&D: a strategy for the millennium? Pharm. Sci. Technol. Today 1 1998 89 90
22. T.A. Roberson et al. Transforming drug development with a fully outsourced model: lessons learned for biopharmaceuticals Pharm. Outsourcing 10 2009 18 22
23. J.L. LaMattina The impact of mergers on pharmaceutical R&D Nat. Rev. Drug Discov. 10 2011 559 560
24. R. Longman Flexion exploits big pharma as discovery supplier In VivoBus. Med. Rep. 28 2010 1 4
25. J. Chakma et al. Is it virtuous to be virtual? The VC viewpoint Nat. Biotechnol. 27 2009 886 888
26. J. Hunter, and S. Stephens Is open innovation the way forward for big pharma? Nat. Rev. Drug Discov. 9 2010 87 88